Sheetal Hardikar

University of Utah
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (64)

Background: Cell-to-cell adhesion and angiogenesis are hallmarks of cancer. No studies have examined associations of adhesion molecules and angiogenesis biomarkers with clinical outcomes in colorectal cancer. Methods: In presurgery serum from n = 426 patients with colorectal cancer (stage I–III), we investigated associations of CRP, SAA, adhesion molecules (sICAM-1, sVCAM-1), and angiogenesis markers (VEGF-A and VEGF-D) with overall survival (OS), disease-free survival (DFS), and risk of recurrence. We computed HRs and 95% confidence intervals; adjusted for age, sex, BMI, stage, site, and study site, stratified by tumor site in exploratory analyses. Results: N = 65 (15%) were deceased, and 39 patients (14%) had a recurrence after a median follow-up of 31 months. We observed significant associations of biomarkers with OS, DFS, and risk of recurrence on a continuous scale and comparing top to bottom tertile, with HRs ranging between 1.19 and 13.92. CRP was associated with risk of death and recurrence in patients in the top tertile compared with patients in the bottom tertile, for example, risk of recurrence HR Q3-Q1 : 13.92 (1.72–112.56). Significant heterogeneity between biomarkers and clinical outcomes was observed in stratified analysis by tumor site for CRP, SAA, sICAM-1, sVCAM-1, and VEGF-D. VEGF-D was associated with a 3-fold increase in risk of death for rectal cancer (HR log2 : 3.26; 95% CI, 1.58–6.70) compared with no association for colon cancer (HR log2 : 0.78; 95% CI, 0.35–1.73; P heterogenity = 0.01). Conclusions: Adhesion molecules and angiogenesis biomarkers are independent prognostic markers for colorectal cancer, with differences by tumor site. Impact: There is need for tailored treatment for colon and rectal cancer.

Year:

2025

Supplemental Table 3 provides effect estimates for the association of incident diabetes and all-cause mortality among obesity-related cancer survivors and cancer-free individuals, stratified by covariates that did not meet PH assumptions.

Year:

2025

Background: Patients with colorectal cancer commonly suffer from complex psychological distress. Elevated distress may be linked to systemic biomarkers. We investigated associations of biomarkers of inflammation and angiogenesis with cancer-related distress (CTXD) score. Methods: N = 315 patients (stage I–IV) from 2 centers of the ColoCare Study were included: Huntsman Cancer Institute and University of Heidelberg. Biomarkers (e.g., IL6, VEGF-A, VEGF-D) were measured in serum collected pre-surgery and 12 months thereafter. The CTXD overall score and 4 subscales were collected 12 months after surgery and dichotomized to investigate biomarkers as predictors of distress 12 months after surgery; adjusted for age, sex, body mass index, tumor stage, center, and baseline levels of biomarkers. Results: Doubling of IL6 predicted future increased risk of overall distress [odds ratio (OR), 1.20; 95% confidence interval (CI), 1.02–1.41; P = 0.03]. VEGF-A–predicted future increased risk of high family strain (VEGF-A: OR, 1.21; 95% CI, 1.01–1.44; P = 0.04) and VEGF-D was associated with medical and financial demands (OR, 1.34; 95% CI, 1.01–1.74; P = 0.03). Conclusions: This is the first study to show that systemic biomarkers are significantly associated with future CTXD score. Distress was not measured at baseline; we cannot rule out ongoing associations of inflammation and distress throughout treatment versus a direct effect of inflammation on distress. Nonetheless, these data add to evidence that biobehavioral processes interact and that systemic biomarkers are associated with cancer-related distress one year after surgery. Impact: Exercise and diet interventions that lower systemic cytokine levels may impact longer-term CTXD score and improve quality of life of patients with colorectal cancer.

Year:

2025

Supplemental Table 6 provides effect estimates for the association of incident diabetes and cancer-specific mortality among obesity-related cancer survivors, stratified my covariates that did not meet PH assumptions.

Year:

2025

The incidence of colorectal cancer in young adults (age of diagnosis Significance: We investigated whether environmentally driven factors contribute to EOCRC. We observed accelerated epigenetic aging in EOCRC and epigenetic changes associated with chronic inflammation. Tumor immune cell abundances correlated more strongly with microbes in EOCRC than in AOCRC. These data suggest a dysregulation of the immune response in EOCRC, driving chronic inflammation and tissue aging.

Year:

2025

Relationship between microbes and immune cell composition. A, All microbe-genus level abundances (columns) correlated to the deconvolved immune cell abundances (rows), with the strength of the association and its direction indicated by color in the TCGA (top row) and ORIEN (bottom row) datasets. Spearman correlations between the deconvolved abundance of ( B ) activated mast cells or ( C ) neutrophils and microbes in both the TCGA and ORIEN datasets. Concordant associations (significant in both and in the same direction) are shown in green, with select taxa labeled. There were no microbes significantly anticorrelated with activated mast cells or neutrophils.

Year:

2025

Accelerated aging with epigenetic signatures in EOCRC. A, Heatmap was drawn with samples (patients) in the row and CpG sites (probes) in the column. The DNAm values range from 0.0 (completely unmethylated, blue) to 1.0 (completely methylated, red). B, The volcano plot demonstrated differential methylated sites (expressed as β values) between EOCRC and AOCRC groups. △β for each CpG site is defined as β value of (EOCRC – AOCRC). FDR-adjusted P P value P value C, Box plot showed the mean β value of patients with EOCRC and AOCRC was 0.46 ± 0.028 and 0.47 ± 0.027 ( P value = 0.13, two-sample t test), respectively. D, Box plots demonstrated the accelerated aging in EOCRC. The DNAm age acceleration (Δ = methylation age − chronologic age) in EOCRC and AOCRC for all samples is shown. The Δ EOCRC predicted by Horvath, Hannum, and PhenoAge models was 2.1, 18.4, and 32.8 years, respectively. The Δ AOCRC predicted by Horvath, Hannum, and PhenoAge was −14.2, 3.4, and 27.1 years, respectively, with P values of 7.89E−12, 1.48E−08, and 0.17, respectively.

Year:

2025

Intratumoral microbes do not show consistent differences in EOCRC. A, Venn diagram demonstrated partial overlap in microbes among three datasets. The abundances of observed genera that passed stringent quality and contamination filters are shown (ORIEN, n = 353 genera; TCGA, n = 357 genera; and 16S, n = 30 genera), with the best agreement between the two RNA-seq datasets. B, The Bray–Curtis dissimilarity plot showed that RNA-seq–derived microbes were most similar to 16S microbes from the same tumor (paired) and least similar to microbes from adjacent normal tissue from another person (unpaired). C, The comparison of the relative abundance of microbes between the 16S-based dataset and the RNA-seq–based datasets (ORIEN and TCGA). D–F, Volcano plots showed no consistent differences in microbes from RNA-seq–based (TCGA, ORIEN) or 16S-based datasets. No microbes passed the significance threshold in EOCRC. G–I, Effect sizes of the most significant taxa across the three analyses showed no similarities in the AOCRC-enriched microbes.

Year:

2025

Methylation signature validation through GE profiles in EOCRC. A, Integration of the differentially methylated sites with paired RNA-seq showed genes that vary in methylation and transcription. The threshold for the FDR-adjusted P values for differences is 0.05 (FDR P value ≤ 0.05). Highlighted genes in orange indicate significant hypomethylation and expression. B, The canonical pathways involved with DMGs in EOCRC have an FDR-adjusted P value C and D, Bubble chart of pathways based on DEGs in EOCRC from TCGA and ORIEN, highlighting those predicted by methylation alone. The color of the pathways is based on their z -score, and the size of the bubble is correlated with the number of genes from the dataset that overlap each pathway. E, Summary of the analyses to validate the differential methylation, with those supported by all three datasets indicated within the box.

Year:

2025

Background Prior studies have documented that patients with colorectal cancer (CRC) are at an increased risk of cardiovascular disease (CVD). Objectives To examine coronary artery calcium (CAC) as a marker of subclinical atherosclerosis and its association with major adverse cardiovascular events (MACE) in patients with CRC across the cancer treatment trajectory. Methods Adults with newly diagnosed CRC were enrolled in the prospective ColoCare study from 2017 to 2024. CAC was measured from routine diagnostic computed tomography (CT) and positron emission tomography‐CT scans at CRC diagnosis until 5 years post‐diagnosis. Atherosclerosis was defined as the presence of CAC. We used multivariable‐adjusted Fine and Gray models to assess the association between CAC and MACE risk, accounting for competing risks. Results Among 300 CRC patients, the most common CVD risk factors at cancer diagnosis were hypertension (37%), hyperlipidemia (24%), and diabetes (14%). During follow‐up (median = 5.3 years), 75 (25%) individuals experienced MACE: stroke (3%), new/worsening HF (9%), HF exacerbation requiring hospitalization (2%), coronary revascularization (3%), and death (19%). Among individuals with imaging at baseline ( n = 101), 37 (36.6%) had CAC, and statins were not prescribed in 11 (55.0%) patients with moderate/high CAC. For those with serial imaging ( n = 61), 31.1% showed worsening CAC and 3% developed new CAC. Baseline CAC conferred a higher risk of MACE (HR = 4.79; 95% CI: 1.05–21.75, p = 0.04) after accounting for cancer‐related deaths as a competing risk. Conclusions Subclinical atherosclerosis and MACE are common among patients with CRC. Integrating CAC from routine cancer imaging can identify patients who may benefit from cardio‐preventive treatment.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (50)

Shama Karanth

Assistant Professor

University of Florida

UNITED STATES
View details

Eric Singer

Professor

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Marc Gunter

International Agency for Research on Cancer

FRANCE
View details

Jiangjiang Zhu

Ohio State University

UNITED STATES
View details

Garnet Anderson

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Aladdin Shadyab

Associate Professor

University of California, San Diego

UNITED STATES
View details

Gregory Riedlinger

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Nicholas Denko

Professor

Ohio State University

UNITED STATES
View details

Aik Choon Tan

Senior Director of Data Science

Huntsman Cancer Institute

UNITED STATES
View details

Fred Tabung

University of South Carolina

UNITED STATES
View details

Marian Neuhouser

Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Fouad Choueiry

Ohio State University

UNITED STATES
View details

Ning Jin

Associate Proffessor

Ohio State University

UNITED STATES
View details

Martin D. McCarter

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Carlos HF Chan

Emory University

UNITED STATES
View details

Karen Syrjala

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Matthew Kalady

Professor

Ohio State University

UNITED STATES
View details

John D. Carpten

City of Hope Comprehensive Cancer Center

UNITED STATES
View details

Alexandra Ikeguchi

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mary Playdon

Assistant Professor

University of Utah

UNITED STATES
View details

Rebecca Dodd

Assistant Professor

The University of Iowa

UNITED STATES
View details

Gabriel Tinoco

Associate Professor of Medicine

Ohio State University

UNITED STATES
View details

Rebecca Seguin-Fowler

Associate Professor

Texas A&M University

UNITED STATES
View details

Anjun Ma

Assistant Professor

Ohio State University

UNITED STATES
View details

Claire Jungyoun Han

Ohio State University

UNITED STATES
View details

Qin Ma

Vice Chair for Research

Ohio State University

UNITED STATES
View details

Cynthia A. Thomson

-

UNITED STATES
View details

Yousef Zakharia

Mayo Clinic Arizona

UNITED STATES
View details

Jean Wactawki-Wende

Dean, Suny Distinguished Professor

University at Buffalo

UNITED STATES
View details

Adetunji T. Toriola

Washington University School of Medicine

UNITED STATES
View details

Dan Spakowicz

Assistant Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Xiaochen Zhang

Assistant Professor

Ohio State University

UNITED STATES
View details

Scott Summers

Co-Director

University of Utah

UNITED STATES
View details

Daniel W. Rosenberg

University of Connecticut Health Center

UNITED STATES
View details

Xiaokui Mo

Research Scientist

Ohio State University

UNITED STATES
View details

David Shibata

University of Tennessee Health Science Center

UNITED STATES
View details

Su Yon Jung

University of California, Los Angeles

UNITED STATES
View details

Ahmad Tarhini

Senior Member, Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

William L. Holland

Associate Professor

University of Utah

UNITED STATES
View details

juhua luo

Professor

Indiana University Bloomington School of Public Health

UNITED STATES
View details

Griffin Caryotakis

Huntsman Cancer Institute

UNITED STATES
View details

Caroline Himbert

Assistant Professor

University of Utah Health Huntsman Cancer Institute

UNITED STATES
View details

Caroline Dravillas

Ohio State University

UNITED STATES
View details

Yangbo Sun

Assistant Professor

University of Tennessee Health Science Center

UNITED STATES
View details

Christopher Li

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

marcia stefanick

Stanford University

UNITED STATES
View details

Ting-Yuan Cheng

Associate Professor

Ohio State University

UNITED STATES
View details

YunZhou Liu

Ohio State University

UNITED STATES
View details

Nazmus Saquib

-

SAUDI ARABIA
View details

Jennifer Ose

Professorin (W2)

Hochschule Hannover

GERMANY
View details